Prostate Cancer最新文献_第9页

Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. 剖析前列腺癌发展过程中的主要信号通路。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-04-29 DOI: 10.1155/2013/920612

Henrique B da Silva, Eduardo P Amaral, Eduardo L Nolasco, Nathalia C de Victo, Rodrigo Atique, Carina C Jank, Valesca Anschau, Luiz F Zerbini, Ricardo G Correa

{"title":"Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.","authors":"Henrique B da Silva, Eduardo P Amaral, Eduardo L Nolasco, Nathalia C de Victo, Rodrigo Atique, Carina C Jank, Valesca Anschau, Luiz F Zerbini, Ricardo G Correa","doi":"10.1155/2013/920612","DOIUrl":"https://doi.org/10.1155/2013/920612","url":null,"abstract":"Prostate cancer (PCa) is one of the most common malignancies found in males. The development of PCa involves several mutations in prostate epithelial cells, usually linked to developmental changes, such as enhanced resistance to apoptotic death, constitutive proliferation, and, in some cases, to differentiation into an androgen deprivation-resistant phenotype, leading to the appearance of castration-resistant PCa (CRPCa), which leads to a poor prognosis in patients. In this review, we summarize recent findings concerning the main deregulations into signaling pathways that will lead to the development of PCa and/or CRPCa. Key mutations in some pathway molecules are often linked to a higher prevalence of PCa, by directly affecting the respective cascade and, in some cases, by deregulating a cross-talk node or junction along the pathways. We also discuss the possible environmental and nonenvironmental inducers for these mutations, as well as the potential therapeutic strategies targeting these signaling pathways. A better understanding of how some risk factors induce deregulation of these signaling pathways, as well as how these deregulated pathways affect the development of PCa and CRPCa, will further help in the development of new treatments and prevention strategies for this disease.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"920612"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/920612","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31483822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 54

HMGB1: A Promising Therapeutic Target for Prostate Cancer. HMGB1:前列腺癌的一个有前景的治疗靶点

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-05-12 DOI: 10.1155/2013/157103

Munirathinam Gnanasekar, Ramaswamy Kalyanasundaram, Guoxing Zheng, Aoshuang Chen, Maarten C Bosland, André Kajdacsy-Balla

引用次数: 43

Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers. 半凝集素作为晚期前列腺癌新的预后标志物和潜在的治疗靶点。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-09-24 DOI: 10.1155/2013/519436

Diego J Laderach, Lucas Gentilini, Felipe M Jaworski, Daniel Compagno

引用次数: 17

Emerging molecularly targeted therapies in castration refractory prostate cancer. 去势难治性前列腺癌新出现的分子靶向治疗。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-05-08 DOI: 10.1155/2013/981684

Jesal C Patel, Benjamin L Maughan, Archana M Agarwal, Julia A Batten, Tian Y Zhang, Neeraj Agarwal

{"title":"Emerging molecularly targeted therapies in castration refractory prostate cancer.","authors":"Jesal C Patel, Benjamin L Maughan, Archana M Agarwal, Julia A Batten, Tian Y Zhang, Neeraj Agarwal","doi":"10.1155/2013/981684","DOIUrl":"https://doi.org/10.1155/2013/981684","url":null,"abstract":"Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate cancer. However, despite initial responses, almost all men eventually develop castration refractory metastatic prostate cancer (CRPC) and die of their disease. Over the last decade, it has been recognized that despite the failure of ADT, most prostate cancers maintain some dependence on androgen and/or androgen receptor (AR) signaling for proliferation. Furthermore, androgen independent molecular pathways have been identified as drivers of continued progression of CRPC. Subsequently, drugs have been developed targeting these pathways, many of which have received regulatory approval. Agents such as abiraterone, enzalutamide, orteronel (TAK-700), and ARN-509 target androgen signaling. Sipuleucel-T, ipilimumab, and tasquinimod augment immune-mediated tumor killing. Agents targeting classic tumorogenesis pathways including vascular endothelial growth factor, hepatocyte growth factor, insulin like growth factor-1, tumor suppressor, and those which regulate apoptosis and cell cycles are currently being developed. This paper aims to focus on emerging molecular pathways underlying progression of CRPC, and the drugs targeting these pathways, which have recently been approved or have reached advanced stages of development in either phase II or phase III clinical trials. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"981684"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/981684","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31550019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 25

Advances in Robotic-Assisted Radical Prostatectomy over Time. 机器人辅助根治性前列腺切除术的进步。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-11-12 DOI: 10.1155/2013/902686

Emma F P Jacobs, Ronald Boris, Timothy A Masterson

引用次数: 0

Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. 骨靶向治疗转移性去势抵抗性前列腺癌:不断发展的范式。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-08-28 DOI: 10.1155/2013/210686

Joelle El-Amm, Ashley Freeman, Nihar Patel, Jeanny B Aragon-Ching

{"title":"Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.","authors":"Joelle El-Amm, Ashley Freeman, Nihar Patel, Jeanny B Aragon-Ching","doi":"10.1155/2013/210686","DOIUrl":"https://doi.org/10.1155/2013/210686","url":null,"abstract":"Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone resorption. While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit. Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well. Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"210686"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/210686","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31762529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

Quantifying the ki-67 heterogeneity profile in prostate cancer. 前列腺癌患者ki-67异质性的定量分析。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-10-03 DOI: 10.1155/2013/717080

Shane Mesko, Patrick Kupelian, D Jeffrey Demanes, Jaoti Huang, Pin-Chieh Wang, Mitchell Kamrava

{"title":"Quantifying the ki-67 heterogeneity profile in prostate cancer.","authors":"Shane Mesko, Patrick Kupelian, D Jeffrey Demanes, Jaoti Huang, Pin-Chieh Wang, Mitchell Kamrava","doi":"10.1155/2013/717080","DOIUrl":"https://doi.org/10.1155/2013/717080","url":null,"abstract":"Background: Ki-67 is a robust predictive/prognostic marker in prostate cancer; however, tumor heterogeneity in prostate biopsy samples is not well studied.Methods: Using an MRI/US fusion device, biopsy cores were obtained systematically and by targeting when indicated by MRI. Prostate cores containing cancer from 77 consecutive men were analyzed. The highest Ki-67 was used to determine interprostatic variation. Ki-67 range (highest minus lowest) was used to determine intraprostatic and intralesion variation. Apparent diffusion coefficient (ADC) values were evaluated in relation to Ki-67.Results: Interprostatic Ki-67 mean ± standard deviation (SD) values for NCCN low (L), intermediate (I), and high (H) risk patients were 5.1 ± 3.8%, 7.4 ± 6.8%, and 12.0 ± 12.4% (ANOVA P = 0.013). Intraprostatic mean ± SD Ki-67 ranges in L, I, and H risk patients were 2.6 ± 3.6%, 5.3 ± 6.8%, and 10.9 ± 12.3% (ANOVA P = 0.027). Intralesion mean ± SD Ki-67 ranges in L, I, and H risk patients were 1.1 ± 0.9%, 5.2 ± 7.9%, and 8.1 ± 10.8% (ANOVA P = 0.22). ADC values at Ki-67 > and <7.1% were 860 ± 203 and 1036 ± 217, respectively (P = 0.0029).Conclusions: High risk patients have significantly higher inter- and intraprostatic Ki-67 heterogeneity. This needs to be considered when utilizing Ki-67 clinically.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"717080"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/717080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31857464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. 循环microrna作为前列腺癌的生物标志物:研究进展。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-03-12 DOI: 10.1155/2013/539680

Nikhil Sapre, Luke A Selth

引用次数: 53

Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer. 血液中omega-3脂肪酸作为前列腺癌风险决定因素的分子生物标志物。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-03-25 DOI: 10.1155/2013/875615

Mishell Kris Sorongon-Legaspi, Michael Chua, Maria Christina Sio, Marcelino Morales

{"title":"Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer.","authors":"Mishell Kris Sorongon-Legaspi, Michael Chua, Maria Christina Sio, Marcelino Morales","doi":"10.1155/2013/875615","DOIUrl":"https://doi.org/10.1155/2013/875615","url":null,"abstract":"Previous researches involving dietary methods have shown conflicting findings. Authors sought to assess the association of prostate cancer risk with blood levels of omega-3 polyunsaturated fatty acids (n-3 PUFA) through a meta-analysis of human epidemiological studies in available online databases (July, 2012). After critical appraisal by two independent reviewers, Newcastle-Ottawa Quality Assessment Scale (NOQAS) was used to grade the studies. Six case control and six nested case control studies were included. Results showed nonsignificant association of overall effect estimates with total or advanced prostate cancer or high-grade tumor. High blood level of alpha-linolenic acid (ALA) had nonsignificant positive association with total prostate cancer risk. High blood level of docosapentaenoic acid (DPA) had significant negative association with total prostate cancer risk. Specific n-3 PUFA in fish oil, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) had positive association with high-grade prostate tumor risk only after adjustment of interstudy variability. There is evidence that high blood level of DPA that is linked with reduced total prostate cancer risk and elevated blood levels of fish oils, EPA, and DHA is associated with high-grade prostate tumor, but careful interpretation is needed due to intricate details involved in prostate carcinogenesis and N-3 PUFA metabolism.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"875615"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/875615","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31360956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. 非洲裔男性前列腺癌发病率、侵袭性和死亡率的全球模式。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-02-13 DOI: 10.1155/2013/560857

Timothy R Rebbeck, Susan S Devesa, Bao-Li Chang, Clareann H Bunker, Iona Cheng, Kathleen Cooney, Rosalind Eeles, Pedro Fernandez, Veda N Giri, Serigne M Gueye, Christopher A Haiman, Brian E Henderson, Chris F Heyns, Jennifer J Hu, Sue Ann Ingles, William Isaacs, Mohamed Jalloh, Esther M John, Adam S Kibel, Lacreis R Kidd, Penelope Layne, Robin J Leach, Christine Neslund-Dudas, Michael N Okobia, Elaine A Ostrander, Jong Y Park, Alan L Patrick, Catherine M Phelan, Camille Ragin, Robin A Roberts, Benjamin A Rybicki, Janet L Stanford, Sara Strom, Ian M Thompson, John Witte, Jianfeng Xu, Edward Yeboah, Ann W Hsing, Charnita M Zeigler-Johnson

{"title":"Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent.","authors":"Timothy R Rebbeck, Susan S Devesa, Bao-Li Chang, Clareann H Bunker, Iona Cheng, Kathleen Cooney, Rosalind Eeles, Pedro Fernandez, Veda N Giri, Serigne M Gueye, Christopher A Haiman, Brian E Henderson, Chris F Heyns, Jennifer J Hu, Sue Ann Ingles, William Isaacs, Mohamed Jalloh, Esther M John, Adam S Kibel, Lacreis R Kidd, Penelope Layne, Robin J Leach, Christine Neslund-Dudas, Michael N Okobia, Elaine A Ostrander, Jong Y Park, Alan L Patrick, Catherine M Phelan, Camille Ragin, Robin A Roberts, Benjamin A Rybicki, Janet L Stanford, Sara Strom, Ian M Thompson, John Witte, Jianfeng Xu, Edward Yeboah, Ann W Hsing, Charnita M Zeigler-Johnson","doi":"10.1155/2013/560857","DOIUrl":"10.1155/2013/560857","url":null,"abstract":"Prostate cancer (CaP) is the leading cancer among men of African descent in the USA, Caribbean, and Sub-Saharan Africa (SSA). The estimated number of CaP deaths in SSA during 2008 was more than five times that among African Americans and is expected to double in Africa by 2030. We summarize publicly available CaP data and collected data from the men of African descent and Carcinoma of the Prostate (MADCaP) Consortium and the African Caribbean Cancer Consortium (AC3) to evaluate CaP incidence and mortality in men of African descent worldwide. CaP incidence and mortality are highest in men of African descent in the USA and the Caribbean. Tumor stage and grade were highest in SSA. We report a higher proportion of T1 stage prostate tumors in countries with greater percent gross domestic product spent on health care and physicians per 100,000 persons. We also observed that regions with a higher proportion of advanced tumors reported lower mortality rates. This finding suggests that CaP is underdiagnosed and/or underreported in SSA men. Nonetheless, CaP incidence and mortality represent a significant public health problem in men of African descent around the world.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"560857"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31295120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0